Apollo Therapeutics and Oxford University enter into drug discovery and development collaboration

The collaboration is driven by the quality of science and the burgeoning innovation environment at Oxford that has elicited a critical mass of early drug development translational research programmes. Together, Apollo and Oxford University could deliver new medicines to help us tackle cancer, autoimmune disease, and more, improving and saving thousands of lives. Apollo Therapeutics has assembled a world leading team of drug discovery and development experts. Dr Richard Mason, Chief Executive Officer of Apollo Therapeutics, said: 'At Apollo Therapeutics we are ambitious in our mission to translate important new research discoveries into valuable new drugs. The University of Oxford joins Apollo’s other five world-class research institutions: the University of Cambridge, Imperial College London, University College London, King’s College London and the Institute of Cancer Research.